Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical has reported that it has acquired DNA delivery and expression assets from Valentis, including the DNAvax polymer delivery system, GeneSwitch technology and rights to some Valentis license agreements.
Subscribe to our email newsletter
Inovio will acquire the rights to agreements Valentis made with IDM Pharma, Innogenetics and Pharmexa. Innogenetics and Pharmexa are currently conducting separate phase I trials of DNA vaccines using the DNAvax polymer delivery system.
The acquisition enhances Inovio’s overall gene delivery platform with the addition of complementary technology and increases the number of gene-based therapeutics under clinical evaluation from four to six.
Inovio has also acquired a number of cationic lipid and certain gene expression technologies. Valentis has also agreed to assign to Inovio rights under existing GeneSwitch license agreements with Berlex Biosciences.
Inovio paid $860,000 for the rights and technology.
Inovio expects that revenue from the GeneSwitch licenses and milestone payments from licensees of the DNAvax technology to contribute to its cash flow.